StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research report sent to investors on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Down 1.0 %
Pulmatrix stock opened at $1.93 on Thursday. The company has a market cap of $7.05 million, a price-to-earnings ratio of -0.80 and a beta of 0.94. The firm’s fifty day moving average is $1.92 and its 200 day moving average is $1.89. Pulmatrix has a 52-week low of $1.55 and a 52-week high of $2.84.
Pulmatrix (NASDAQ:PULM – Get Free Report) last posted its quarterly earnings data on Friday, May 10th. The biotechnology company reported $0.23 earnings per share for the quarter. The business had revenue of $5.89 million for the quarter. Pulmatrix had a negative net margin of 75.73% and a negative return on equity of 44.05%.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Further Reading
- Five stocks we like better than Pulmatrix
- How to invest in blue chip stocks
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- ETF Screener: Uses and Step-by-Step Guide
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Where Do I Find 52-Week Highs and Lows?
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
